Source: Getty Images
Genetic research. Computer artwork showing a DNA microarray and Leonardo da Vinci's vitruvian man.

Paradigm Diagnostics has attracted a second investor for its $7 million Series B financing. Science-focused venture capital firm New Science Ventures will invest $3 million in the data-driven molecular diagnostics company, joining Mesa Verde Venture Partners, which invested $3.5 million in late 2016.

According to the company, the money raised will be used to accelerate adoption its Paradigm Cancer Diagnostic Test, PCDx, a comprehensive genomic profiling test. It will also work to expand its Paradigm cancer registry.

“Our ability to provide high-quality and comprehensive genomic testing results within 4­–5 business days, often on specimens with a very limited amount of tumor, continues to elevate us in the market” said David Mallery, president and CEO.

PCDx is an NGS-based diagnostic that provides clinical decision support to treating physicians. The test analyzes DNA, RNA via NGS, and protein by immunohistochemistry to provide data on the molecular alterations driving a patient’s cancer and drugs that can directly impact therapeutic decision-making.

According to Grace Colón, Ph.D., of New Science Ventures, who will join the Paradigm board of directors, noted Paradigm’s broad-focused approach on clinically actionable biomarkers spanning RNA, DNA, and protein—all validated through peer-reviewed publications—is what attracted the multimillion-dollar investment.

“Through this investment we hope to help accelerate the utilization of PCDx, their leading comprehensive genomic profiling service,” Dr. Colón added.

This site uses Akismet to reduce spam. Learn how your comment data is processed.